| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.013 | 0.6 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.6 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |